Synchrony Medical, a Jersey City, NJ-based respiratory care technology company and creator of the FDA-cleared LibAirway Airway Clearance system, has raised $5 million in a funding series led by Edge Medical Ventures.
The round also saw participation from the New Jersey Economic Development Authority (NJEDA), Broadfin Holdings, Consensus Business Group (CBG), and angel investors.
Read More:Rainfall Health Raises $15M in Series A Funding
The company plans to use the funds to accelerate its U.S. expansion, continue clinical research and product development, and expand patient access to LibAirty.
“This funding helps us bring effective, easy-to-use airway clearance into more homes, allowing patients to manage their respiratory health better,” said Anat Shani, CEO of Synchrony Medical. “With the support of our investors and new board members, we’re ready to grow our U.S. presence expand clinical research and continue innovating our products.”
Synchrony Medical is a respiratory care technology company and the maker of the FDA-cleared LibAirty™ Airway Clearance System. For millions of people with chronic lung conditions, clearing the airways is critical to managing symptoms, preventing infections, and slowing disease progression. The LibAirty™ system provides this therapy through a daily at home treatment and has been shown to clear up to twice as much mucus as traditional methods with greater comfort and patient satisfaction. Since launching commercially in late 2025 LibAirty™ has received strong support from both patients and clinicians, showing an immediate impact on daily disease management.
Synchrony will continue to grow its U.S. team and operations from its headquarters in Jersey City. The funding also includes $1 million from the New Jersey Economic Development Authority through the New Jersey Innovation Evergreen Fund’s co-investment with Edge Medical Ventures, helping support the company’s growth and presence in the state.
“The LibAirty™ System, with its proven clinical benefits, is ready to make a big impact in a growing market,” said Kevin Kotler, General Partner of Broadfin Holdings. “We’re excited to work with the team to expand nationwide, and deliver real value to patients and shareholders.”
“Synchrony represents the kind of innovation we aim to support, tackling an unmet clinical need with strong evidence and a clear plan to improve patient care,” said Shai Policker, Chairman of Synchrony and Managing Partner at Edge Medical Ventures. “This shows how Edge’s global reach, together with the company’s strong execution, can set a new standard of care and bring it to market.”
“As partners of EdgeLabs (formerly MEDX Xelerator), we are proud to have supported Synchrony from its early days and seen its impressive progress,” said Vincent Tchenguiz, Chairman of Consensus Business Group. “We are excited to keep supporting this important medical innovation and help make it available to more patients.”
Along with the funding, Synchrony announced that Kevin Kotler, General Partner at Broadfin Holdings, and Elad Duschak, Strategic Advisor to CBG for Healthcare, have joined the company’s Board of Directors. Their appointments will strengthen leadership and strategy as the company moves into its next phase of growth.
About Synchrony Medical
Founded in 2020 by CEO Anat Shani, Synchrony Medical is a respiratory care technology company focused on providing advanced at-home airway clearance therapy. Its FDA-cleared LibAirty™ Airway Clearance System makes respiratory treatment easy to manage at home, helping patients with chronic lung disease perform therapy independently and setting a new standard of care. Developed with leading pulmonologists at Sheba Medical Center, LibAirty™ was launched through Edge Medical Ventures’ EdgeLabs (formerly MEDX Xelerator) and is supported by the Israel Innovation Authority. Synchrony Medical is headquartered in Jersey City, New Jersey, with additional operations in Or Yehuda, Israel.
Read More:inKind Raises $450M in Funding
